- Home
- TAP vs MRNA Comparison
TAP vs MRNA Comparison
Compare TAP & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAP
- MRNA
- Stock Information
- Founded
- TAP 1873
- MRNA 2010
- Country
- TAP United States
- MRNA United States
- Employees
- TAP N/A
- MRNA N/A
- Industry
- TAP Beverages (Production/Distribution)
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAP Consumer Staples
- MRNA Health Care
- Exchange
- TAP Nasdaq
- MRNA Nasdaq
- Market Cap
- TAP 10.1B
- MRNA 9.8B
- IPO Year
- TAP N/A
- MRNA 2018
- Fundamental
- Price
- TAP $45.69
- MRNA $27.89
- Analyst Decision
- TAP Hold
- MRNA Hold
- Analyst Count
- TAP 14
- MRNA 17
- Target Price
- TAP $53.57
- MRNA $42.40
- AVG Volume (30 Days)
- TAP 2.7M
- MRNA 12.3M
- Earning Date
- TAP 11-04-2025
- MRNA 11-06-2025
- Dividend Yield
- TAP 4.12%
- MRNA N/A
- EPS Growth
- TAP N/A
- MRNA N/A
- EPS
- TAP 5.06
- MRNA N/A
- Revenue
- TAP $11,283,200,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- TAP N/A
- MRNA N/A
- Revenue Next Year
- TAP $0.52
- MRNA $9.75
- P/E Ratio
- TAP $9.02
- MRNA N/A
- Revenue Growth
- TAP N/A
- MRNA N/A
- 52 Week Low
- TAP $43.80
- MRNA $23.15
- 52 Week High
- TAP $64.66
- MRNA $59.73
- Technical
- Relative Strength Index (RSI)
- TAP 42.66
- MRNA 58.77
- Support Level
- TAP $45.64
- MRNA $26.91
- Resistance Level
- TAP $46.47
- MRNA $28.99
- Average True Range (ATR)
- TAP 0.95
- MRNA 1.22
- MACD
- TAP 0.18
- MRNA 0.35
- Stochastic Oscillator
- TAP 60.64
- MRNA 76.78
About TAP Molson Coors Beverage Company Class B
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.